Key facts
- SMAVIEW’s last known valuation is $14.7M (Feb 2023).
- It has raised $1.5M; the latest was Early Stage VC in Sep 2025.
- Notable investors include Shenzhen Yifeng Investment Management Enterprise, Decent Capital, Optics Valley Industry Investment, Optics Valley Financial Holdings Group, Hubei Yangtze River Industrial Investment Group.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for SMAVIEW
- ·The full record, as it builds
Funding rounds
No funding rounds for SMAVIEW are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About SMAVIEW
Developer of an in vivo drug screening super-resolution microscope intended to promote the development of the industry. The company's product uses the original light field control light sheet microscopy technology and brain-inspired AI image enhancement and analysis algorithm, which can efficiently analyze the dynamics of life structures information, providing richer structural, pathological and biological information for disease diagnosis.
- Sector
- Healthcare
- HQ
- Wuhan, China
- Founded
- 2022
- Website
- smart-view.com.cn/
- Ownership
- Privately Held (backing)
SMAVIEW doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in SMAVIEW shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on SMAVIEW in its N-PORT filings yet. We sweep new filings monthly.